Cancer Discov. 2016 Nov;6(11):1200. doi: 10.1158/2159-8290.CD-NB2016-122. Epub 2016 Oct 3.
Researchers found that the magnitude of reinvigoration of CD8+ T cells-the peak level of Ki67 after treatment-compared with tumor burden prior to treatment with the PD-1 inhibitor pembrolizumab correlated with clinical response in patients with advanced melanoma. If this finding is confirmed in a larger cohort of patients, the ratio of these two factors could be used to determine whether a patient should continue with pembrolizumab therapy or switch to a different treatment or combination of treatments.
研究人员发现，与接受 PD-1 抑制剂帕博利珠单抗治疗前的肿瘤负担相比，CD8+T 细胞的再激活程度（治疗后 Ki67 的峰值水平）与晚期黑色素瘤患者的临床反应相关。如果这一发现在更大的患者队列中得到证实，那么这两个因素的比值可用于确定患者是否应继续接受帕博利珠单抗治疗，还是应转为其他治疗或联合治疗。
